Global Neurology Academy

Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Clinician's Roundtable
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
- Stephen Wong, PhD
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Global Neurology Academy
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
- Ashley Baker, MSN, PMHNP
- Jay Avasarala, MD, PhD
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiers
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
- Sergio Baranzini, PhD
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiers
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
- Michael Levy, MD, PhD
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiers
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
- Le Hua, MD
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiers
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
- Ryan Quigley
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiers
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiers
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms

Medical News

Medical News
Beyond the Impact: New Insights into CTE and Contact Sport Safety
11/04/2025
Read more
Medical News
Understanding HIV Persistence: The Role of Perineural Pathways
11/04/2025
Read more
Medical News
Physical Activity as a Modifiable Risk Factor in Preclinical Alzheimer’s Disease
11/04/2025
Read more
Medical News
Transformative Potential of 'Molecular Glues' in Precision Medicine
11/04/2025
Read more

See more news

CME/CE

Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits
From Resistance to Response: Evolving Strategies in MDD Management
From Resistance to Response: Evolving Strategies in MDD Management
CME/CE Broadcast Replay
From Resistance to Response: Evolving Strategies in MDD Management
1.00 credit
- Joseph F. Goldberg, MD
1.00 credit
New Frontiers in the Treatment of DMD Across the Age Spectrum
New Frontiers in the Treatment of DMD Across the Age Spectrum
CME/CE
New Frontiers in the Treatment of DMD Across the Age Spectrum
1.00 credit
- Crystal Proud, MD
- John Brandsema, MD
- Omer Abdul Hamid, MD
1.00 credit
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
CME/CE
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
0.75 credits
- Vera Bril, MD
- Neelam Goyal, MD
0.75 credits

Clinical Practice

Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
CME/CE
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
0.25 credits
- Christoph U. Correll, MD
- Jonathan M. Meyer
0.25 credits
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Global Neurology Academy
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
- Vikram V. Bhise, MD
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
NeuroFrontiers
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
- Marc Haut, PhD
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiers
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
- Marc Haut, PhD

Programs

Modern MS Management: Leveraging Technology to Support Brain Health
Modern MS Management: Leveraging Technology to Support Brain Health
Global Neurology Academy
Modern MS Management: Leveraging Technology to Support Brain Health
- Victoria Leavitt, PhD
- Gates B. Colbert, MD
Addressing Barriers to MenB and MenACWY Vaccination
Addressing Barriers to MenB and MenACWY Vaccination
Global Neurology Academy
Addressing Barriers to MenB and MenACWY Vaccination
The Future of MS Management: Novel Agents and Clinical Approaches
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiers
The Future of MS Management: Novel Agents and Clinical Approaches
- Marisa McGinley, DO
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiers
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis